The ER+ breast cancer group included patients with luminal A and luminal B cancers, the ER− breast cancer group included patients with basal‐like, HER2+ In total, 66 patients experienced distant relapse and 49 of those patients with distant relapse died from breast cancer‐related causes within a median follow‐up period of 64 months. Here, ERBB2 is linked to breast carcinoma.